Mike Hollan

Enabling highly individualized treatment approaches that align with each patient’s unique physiology, goals, and tolerability, compounding can have a significant impact.

Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.

Samsung Bioepis’ SVP and head of US commercial discusses the pricing, regulatory, and broader issues impacting the biosimilars market.

Market analysts are comparing Foundayo’s sales with other GLP-1 medications, such as the oral version of Wegovy.

The President also announced a number of other key leadership appointments at federal health agencies.

ARS Pharmaceutical’s CEO discusses how reformulating drugs and updating delivery design can improve the rate of patient adherence to medication.

Samsung Bioepis’ Thomas Newcomer explains the reasons why biosimilar developers are or are not feeling confident about the consistency of the US market in the coming years.

The IRA and MFN are affecting decisions made all throughout the entire drug development process.

Thomas Newcomer of Samsung Bioepis discusses how certain classes of drugs don’t have enough biosimilars in development and the impact that this can have in the coming years.

Identiv’s VP of healthcare discusses the impact of new technology and data collection on trial design.

Citeline’s VP of commercial, patient engagement, and recruitment discusses how clinical trial design must adapt to modern issues.

The Phenomix CEO discusses recent data that suggests that patients may not be prepared for the side effects and unexpected costs of GLP-1s.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

Phenomix CEO Mark Bagnall discusses the effectiveness of GLP-1s and how obesity impacts different patients in a variety of complex ways.

Phenomix CEO Mark Bagnall explains how GLP-1 users often face significant costs to deal with the side effects of GLP-1 usage.

GLP-1 side effects can be serious, and Phenomix CEO Mark Bagnall discusses the impact they can have on patients, who are not always fully educated.

Imunon’s CEO discusses how FDA allowing the Bayesian method impacts innovation in the clinical trial space.

Phenomix CEO Mark Bagnall discusses the reasons for GLP-1 failure and why it’s common for patients to stop taking the medication.

Members of PacBio and iHope discuss collaboration and the global state of genomic testing.

Pharmaceutical companies that made MFN deals with the Trump administration will be exempt from the tariffs, along with other exemptions.

ADVI’s head of market access policy strategy discusses how the Trump administration’s efforts.

Soley Therapeutics’ CEO and co-founder discusses the importance of understanding why some cells survive under stress and others don’t.

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future.

Yerem Yeghiazarians, MD, explains how understanding how various cells react differently to stress impacts how damaged cells may potentially be treated.

Drug pricing restrictions are likely to impact drug launches, especially for medications expected to be sought after by Medicare patients.

As opposed to starting with a target disease, Yerem Yeghiazarians, MD discusses how Soley instead focused on developing a method of identifying broad compounds.

While they may be linked, the administration’s DTC drug coupon site is not necessarily the entirety of its MFN efforts.

Yerem Yeghiazarians, MD, discusses the importance of understanding why certain cells (like cancer cells) can survive in situations that would kill other healthy cells.

For pharma products, ensuring proper delivery requires the majority of work to occur before the product hits the road.

eHealth’s vice president of consumer enablement discusses pricing and cost issues with GLP-1s.